P0506 AZD7798, a monoclonal antibody depleting CCR9+ T cells, with the potential to target hard-to-treat small bowel Crohn’s disease

• Abstract

P1116 Imaging of CCR9 in the small bowel of patients with Crohn’s disease: effects of the CCR9-depleting monoclonal antibody AZD7798

• Abstract

P0151 Multi-modal single cell sequencing identifies CCR9 expression in lamina propria with highest protein expression on CD4 tissue resident memory cells in the inflamed ileum in Crohn’s disease

• Abstract

P014 First-time-in-human visualisation of CCR9 expression in the gut by positron emission tomography

• Abstract

P384 A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn’s Disease: first results of a prospective cohort

• Abstract

P312 Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn’s Disease: towards a new therapeutic drug monitoring tool

• Abstract

P760 Monitoring of laboratory parameters during thiopurine maintenance therapy in patients with inflammatory bowel disease: An unnecessary burden? Get access

• Abstract

P456 Drug survival of thiopurine–allopurinol combination therapy in a real-life population-based cohort Get access

• Abstract

P343 Skewed thiopurine metabolism leads to early therapeutic failure in the majority of patients with inflammatory bowel disease Get access

The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study Get access

• Abstract